01067nas a2200313   4500000000100000000000100001008004100002653001100043653004000054653004400094653005600138653006100194653004600255653001900301653004300320653005700363100001500420700001000435700001100445700001600456700001300472700001400485700001500499245017200514250001500686300001200701490000800713020003200721       2022                            d10aHumans10aHypoglycemic Agents/adverse effects10a*Diabetes Mellitus, Type 2/drug therapy10a*Dipeptidyl-Peptidase IV Inhibitors/adverse effects10a*Sodium-Glucose Transporter 2 Inhibitors/adverse effects10aGlucagon-Like Peptide-1 Receptor/agonists10aCohort Studies10aSulfonylurea Compounds/adverse effects10a*Pulmonary Disease, Chronic Obstructive/drug therapy1 aR. Pradhan1 aS. Lu1 aH. Yin1 aO. H. Y. Yu1 aP. Ernst1 aS. Suissa1 aL. Azoulay00aNovel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study  a2022/11/02  ae0713800 v379  a0959-8138 (Print)
0959-8138